Cancer Drugmaker Parabilis Seeks $475 Million in US IPO
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.